RE:NASH market and competitionDiet (reduction of refined fructose intake which includes sucrose) and 20 minutes walking per day would solve the high prevalence of metabolic disorder we see. It's not hard to do, but the message does not come across to a wide audience. Fructose should be eneny #1 like nicotine was, but the problem is not even recognized. Chronic long term overconsumption of refined fructose (high fructose corn syrup and sucrose) is the main problem. Again, it's the long term chronic use that is the problem, same as alcohol or tobacco.
jeffm34 wrote: There is a reason analysts are not assigning much value for Thera's NASH program. The market is huge but not for Egrifta. Oral meds will dominate the NASH treatment market unless there is a significant advantage with a particular injectable drug. Similar results to using Egrifta can be achieved through diet, exercise and weight loss.
"
The first line of treatment for NAFLD and NASH is weight loss, done through a combination of calorie reduction, exercise, and healthy eating. Weight loss can reduce fat and inflammation in the liver. "
Spending money and resources on a NASH program is not the most effective use of company resources right now. License it out if they want to pursue this market.
https://www.pharmaceuticalonline.com/doc/analysis-of-the-non-alcoholic-steatohepatitis-nash-drug-pipeline-market-sizing-up-the-first-wave-0001 The opportunity for TH in oncology is multiple times larger and 4-5 years sooner than any NASH potential. That is where all resources should be directed.